RxDoctor Payments Data

Shaukat Thanawalla, MD

Internal Medicine · Union, MONPI 1457393134

Payments from drug & device makers

$8,069in general payments, 2019–2025

Across 502 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$810
  • Pfizer$732
  • AstraZeneca$563
  • Amgen$545
  • Boehringer Ingelheim$471
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,89298%
  • Education$1772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,069 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$97,358
Medicare patients
272
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin244$242,593
EliquisApixaban332$191,525
OzempicSemaglutide115$171,743
MounjaroTirzepatide69$84,899
XareltoRivaroxaban75$59,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$48,137
JanuviaSitagliptin Phosphate33$30,167
MyrbetriqMirabegron63$28,937
SymbicortBudesonide/Formoterol Fumarate91$23,150
Tresiba Flextouch U-200Insulin Degludec23$20,506
LinzessLinaclotide13$19,554
Combivent RespimatIpratropium/Albuterol Sulfate32$19,267
Tresiba Flextouch U-100Insulin Degludec11$15,667
Lantus SolostarInsulin Glargine,hum.Rec.Anlog112$15,402
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$12,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$471$261,860276 claims
PfizerEliquis$732$191,525332 claims
Novo NordiskOzempic$810$171,743115 claims
Lilly USA, LLCMounjaro$378$84,89969 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$402$72,497126 claims
Johnson & JohnsonXarelto$97$59,24675 claims
AstraZenecaSymbicort, Farxiga$563$32,843104 claims
MerckJanuvia$360$30,16733 claims
Astellas Pharma US IncMyrbetriq$260$28,93763 claims
AbbVieLinzess$1,022$19,55413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Union

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →